In today’s increasingly competitive business climate, our customers in a range of industries and environments are looking for ways to measurably increase productivity while extending the use of advanced analytical technologies to more routine applications
ORLANDO, Fla.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today introduced innovations that enable customers to improve laboratory productivity – by delivering results faster and with greater accuracy – while extending the boundaries of routine analysis. During Pittcon, being held from March 11-15, in Orlando, the company will showcase its scale and depth of capabilities across its three premier brands: Thermo Scientific®, Fisher Scientific® and Unity™ Lab Services.
Thermo Scientific booth 2665 highlights the company’s industry-leading technology offering, including chromatography, mass spectrometry, and trace elemental and molecular spectroscopy product lines. Within Fisher Scientific booth 2871, customers can learn about the RESULTS™ program, which makes it easier to purchase the products and supplies needed for an entire application. The company’s newest brand, Unity Lab Services, combines product and operations support to create a single solution, and is featured in booths 2665 and 2871.
“In today’s increasingly competitive business climate, our customers in a range of industries and environments are looking for ways to measurably increase productivity while extending the use of advanced analytical technologies to more routine applications,” said Marc N. Casper, president and chief executive officer of Thermo Fisher Scientific. “From the chromatography powerhouse we’ve created by acquiring Dionex, to our new Unity Lab Services capability, we can deliver a tightly integrated value proposition to customers based on the most comprehensive offering in the industry.”
Greater Speed, Accuracy and Efficiency for a Range of Applications
For the first time at Pittcon, customers will see the result of combining Thermo Scientific and Dionex™: a chromatography powerhouse with an extensive offering of new instruments, consumables, columns and software.
Among the chromatography innovations featured are two new high-pressure capillary ion chromatography (IC) systems. The Thermo Scientific Dionex ICS-4000 is the world’s first commercially available integrated capillary high-pressure ion chromatography (HPIC™) system, ideal for analyses in industries such as environmental, food and beverage, pharmaceutical and biopharma. The Thermo Scientific Dionex ICS-5000 is a modular system that offers high-pressure capabilities to bring near-UHPLC performance to IC.
Thermo Fisher is also launching a compact, versatile gas chromatography system. The Thermo Scientific Trace™ 1300 instrument features patent-pending innovations, including plug-n-play injectors and detectors designed to dramatically improve laboratory productivity and lower cost in QA/QC and routine laboratories working on environmental, chemical and food safety applications.
The new Thermo Scientific iCAP™ Q system brings innovation to inductively coupled plasma mass spectrometry (ICP-MS). It features unique ion-focusing technology that delivers improved signal-to-noise performance and increases laboratory throughput by up to 50 percent when compared to current systems. The iCAP Q is ideal for environmental, metals, clinical research, food safety, semiconductor and geochemical laboratories conducting both routine and complex elemental analyses.
Making its Pittcon debut is the Thermo Scientific Q Exactive™ high-performance benchtop Orbitrap™ LC-MS/MS, the first commercially available instrument to bring together high-performance quadrupole MS capability with the ultrahigh-resolution accurate mass Orbitrap platform. Customers can be more confident in the qualitative and quantitative results from the Q Exactive mass spectrometer than from existing quadrupole time-of-flight (Q-Tof) instruments on the market. In laboratories where researchers are performing protein identification, metabolism, forensic toxicology or food safety analyses, “Quanfirmation™” makes it possible to identify, quantify and confirm in one experiment – significantly improving productivity and creating a more efficient workflow.
The company continues its leadership in the miniaturization of technology by introducing the Thermo Scientific NanoDrop® Lite instrument, a compact, personal microvolume UV-Vis spectrophotometer that complements full-featured NanoDrop instruments and places advanced analysis in the hands of every researcher.
And finally, Thermo Fisher recently launched the Thermo Scientific TruNarc™ narcotics analyzer, a handheld instrument that allows law enforcement personnel to rapidly and reliably identify illicit drugs at the scene of a crime.
Enterprise-Level Services and Support Drive Customer Productivity
Thermo Fisher recently launched Unity Lab Services to address productivity at the highest level in a laboratory environment. This unique combination of service and support provides a range of capabilities, from traditional laboratory instrument and equipment maintenance services to enterprise-level support, including management of laboratory staffing and consumables inventory. These services can be implemented across a broad range of laboratory environments and can be scaled from service on a single instrument to a highly customized, comprehensive service program at the laboratory, site or enterprise level.
Laboratory managers will also benefit from the Thermo Scientific CONNECTS for the Paperless Lab™ software solution. The CONNECTS system leverages existing investments in software systems, databases and laboratory instrumentation from a variety of vendors to transform that data into information that can be used across the enterprise. CONNECTS reduces the time and cost associated with manual data handling and improves data integrity.
For access to all Thermo Fisher news and product photos related to Pittcon 2012, please visit our online media room at www.thermofisher.com/news.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenues of $12 billion, we have approximately 39,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through three premier brands, Thermo Scientific, Fisher Scientific and Unity™ Lab Services, which offer a unique combination of innovative technologies, convenient purchasing options and a single solution for laboratory operations management. Our products and services help our customers solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Visit www.thermofisher.com.
The following constitutes a “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the company’s Annual Report on Form 10-K for the year ended December 31, 2011, under the caption “Risk Factors,” which is on file with the Securities and Exchange Commission and available in the “Investors” section of our website under the heading “SEC Filings.” Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: the need to develop new products and adapt to significant technological change; implementation of strategies for improving growth; general worldwide economic conditions and related uncertainties; dependence on customers' capital spending policies and government funding policies; the effect of exchange rate fluctuations on international operations; the effect of healthcare reform legislation; use and protection of intellectual property; the effect of changes in governmental regulations; and the effect of laws and regulations governing government contracts, as well as the possibility that expected benefits related to the acquisitions of Dionex and Phadia may not materialize as expected. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if estimates change and, therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.